Phase II PI3K inhibitor in relapsed, indolent or aggressive NHL
Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas (Non-Hodgkin-Lymphom, lymphatisch, blutbildend, follikuläres Lymphom, maligne Lymphome)